Associations of angiotensin targeting antihypertensive drugs with mortality and hospitalization in primary care patients with dementia

Journal of Alzheimer's Disease

Volumn 33, Issue 4, 2013, Pages 999-1008

  Kehoe, Patrick Gavin ^a   Davies, Neil Martin ^a   Martin, Richard Michael ^a   Ben Shlomo, Yoav ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Alzheimer's disease; amyloid; angiotensin; dementia; hospitalization; mortality; vascular dementia

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

AGED; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; DEMENTIA; DRUG EXPOSURE; FEMALE; FOLLOW UP; GENERAL PRACTICE; HOSPITALIZATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIINFARCT DEMENTIA; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RISK ASSESSMENT; SURVIVAL; UNITED KINGDOM;

EID: 84873696805     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2012-121090     Document Type: Article

References (45)

1. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDAWork Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944
2. Miners JS, Baig S, Palmer J, Palmer LE, Kehoe PG, Love S (2008) Abeta-degrading enzymes in Alzheimer's disease. Brain Pathol 18, 240-252
3. Schneider JA, Arvanitakis Z, Leurgans SE, BennettDA(2009) The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann Neurol 66, 200-208
4. Grinberg LT, Heinsen H (2010) Toward a pathological definition of vascular dementia. J Neurol Sci 299, 136-138
5. Lemolo F, Duro G, Rizzo C, Castiglia L, Hachinski V, Caruso C (2009) Pathophysiology of vascular dementia. Immun Ageing 6, 13
6. Korczyn AD (2005) The underdiagnosis of the vascular contribution to dementia. J Neurol Sci 229-230, 3-6
7. Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, Amaducci L, Orgogozo JM, Brun A, Hofman A, et al. (1993) Vascular dementia: Diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 43, 250-260
8. Skoog I, Gustafson D (2006) Update on hypertension and Alzheimer's disease. Neurol Res 28, 605-611
9. Davies NM, Kehoe PG, Ben-Shlomo Y, Martin RM (2011) Associations of anti-hypertensive treatments with Alzheimer's disease, vascular dementia, and other dementias. J Alzheimers Dis 26, 699-708
10. Li NC, Lee A, Whitmer RA, Kivipelto M, Lawler E, Kazis LE, Wolozin B (2010) Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: Prospective cohort analysis. BMJ 340, b5465
11. Staessen JA, Thijs L, Richart T, Odili AN, Birkenhager WH (2011) Placebo-controlled trials of blood pressure-lowering therapies for primary prevention of dementia. Hypertension 57, e6-e7
12. Kehoe PG, Miners S, Love S (2009) Angiotensins in Alzheimer's disease -friend or foe? Trends Neurosci 32, 619-628
13. Danielyan L, Klein R, Hanson LR, Buadze M, Schwab M, Gleiter CH, Frey WH (2010) Protective effects of intranasal losartan in the APP/PS1 transgenic mouse model of Alzheimer disease. Rejuvenation Res 13, 195-201
14. Mogi M, Li JM, Tsukuda K, Iwanami J, Min LJ, Sakata A, Fujita T, Iwai M, Horiuchi M (2008) Telmisartan prevented cognitive decline partly due to PPAR-gamma activation. Biochem Biophys Res Commun 375, 446-449
15. Mogi M, Tsukuda K, Li JM, Iwanami J, Min LJ, Sakata A, Fujita T, Iwai M, Horiuchi M (2007) Inhibition of cognitive decline in mice fed a high-salt and cholesterol diet by the angiotensin receptor blocker, olmesartan. Neuropharmacology 53, 899-905
16. Wang J, Ho L, Chen L, Zhao Z, Zhao W, Qian X, Humala N, Seror I, Bartholomew S, Rosendorff C, Pasinetti GM (2007) Valsartan lowers brain beta-Amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease. J Clin Invest 117, 3393-3402
17. Eckman EA, Adams SK, Troendle FJ, Stodola BA, Kahn MA, Fauq AH, Xiao HD, Bernstein KE, Eckman CB (2006) Regulation of steady-state beta -Amyloid levels in the brain by neprilysin and endothelin-converting enzyme, but not angiotensin-converting enzyme. J Biol Chem 281, 30471-30478
18. Hemming ML, Selkoe DJ, Farris W (2007) Effects of prolonged angiotensin-converting enzyme inhibitor treatment on amyloid beta-protein metabolism in mouse models of Alzheimer disease. Neurobiol Dis 26, 273-281
19. Ferrington L, Miners JS, Palmer LE, Bond SM, Povey JE, Kelly PAT, Love S, Horsburgh KJ, Kehoe PG (2011) Angiotensin II-inhibiting drugs have no effect on intraneuronal A Or oligomeric A Levels in a triple transgenic mouse model of Alzheimer's disease. Am J Transl Res 3, 197-208
20. Hemming ML, Selkoe DJ (2005) Amyloid beta -protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor. J Biol Chem 280, 37644-37650
21. Hu J, Igarashi A, Kamata M, Nakagawa H (2001) Angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide (A beta); RetardsAbeta aggregation, deposition, fibril formation; And inhibits cytotoxicity. J Biol Chem 276, 47863-47868
22. Oba R, Igarashi A, Kamata M, Nagata K, Takano S, Nakagawa H (2005) The N-Terminal active centre of human angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide. Eur J Neurosci 21, 733-740
23. Sun X, Becker M, Pankow K, Krause E, Ringling M, Beyermann M, Maul B, Walther T, Siems W-E (2008) Catabolic attacks of membrane-bound angiotensin-converting enzyme on the N-Terminal part of species-specific amyloid-[beta] peptides. Eur J Pharmacol 588, 18-25
24. Toropygin IY, Kugaevskaya EV, Mirgorodskaya OA, Elisseeva YE, Kozmin YP, Popov IA, Nikolaev EN, Makarov AA, Kozin SA (2008) The N-domain of angiotensinconverting enzyme specifically hydrolyzes the Arg-5-His-6 bond of Alzheimer's Abeta-(1-16) peptide and its isoAsp-7 analogue with different efficiency as evidenced by quantitative matrix-Assisted laser desorption/ionization time-of-flight mass spectrometry. Rapid Commun Mass Spectrom 22, 231-239
25. Kehoe PG, Wilcock GK (2006) The renin angiotensin system in Alzheimer's disease -updates highlight a clinical and biological dichotomy? Curr Alzheimer Res 3, 171-173
26. Kehoe PG, Wilcock GK (2007) Is inhibition of the reninangiotensin system a new treatment option for Alzheimer's disease? Lancet Neurol 6, 373-378
27. Hajjar I, Hart M, Chen Y-L, Mack W, Milberg W, Chui H, Lipsitz L (2012) Effect of antihypertensive therapy on cognitive function in early executive cognitive impairment: A double-blind randomized clinical trial. Arch Intern Med 172, 442-444
28. Moorhouse P, Song X, Rockwood K, Black S,Kertesz A, Gauthier S, Feldman H (2010) Executive dysfunction in vascular cognitive impairment in the consortium to investigate vascular impairment of cognition study. J Neurol Sci 288, 142-146
29. McGuinness B, Barrett SL, Craig D, Lawson J, Passmore AP (2010) Executive functioning in Alzheimer's disease and vascular dementia. Int J Geriatr Psychiatry 25, 562-568
30. Kehoe PG (2009) Angiotensins and Alzheimer's disease: A bench to bedside overview. Alzheimers Res Ther 1, 3
31. GPRD (2010) The database. http://www.gprd.com/products/database.aspp
32. Office for National Statistics (2000)Key health statistics from general practice 1998. ONS, London
33. Khan NF, Harrison SE, Rose PW (2010) Validity of diagnostic coding within the General Practice Research Database: A systematic review. Br J Gen Pract 60, e128-e136
34. Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ (2010) Validation and validity of diagnoses in the General Practice Research Database: A systematic review. Br J Clin Pharmacol 69, 4-14
35. Dunn N, Mullee M, Perry VH, Holmes C (2005) Association between dementia and infectious disease: Evidence from a case-control study. Alzheimer Dis Assoc Disord 19, 91-94
36. Seshadri S, Zornberg GL, Derby LE, Myers MW, Jick H, Drachman DA (2001) Postmenopausal estrogen replacement therapy and the risk of Alzheimer disease. Arch Neurol 58, 435-440
37. Khachaturian AS, Zandi PP, Lyketsos CG, Hayden KM, Skoog I, Norton MC, Tschanz JT, Mayer LS,Welsh-Bohmer KA, Breitner JC (2006) Antihypertensive medication use and incident Alzheimer disease: The Cache County Study. Arch Neurol 63, 686-692
38. Sink KM, Leng X, Williamson J, Kritchevsky SB, Yaffe K, Kuller L, Yasar S, Atkinson H, Robbins M, Psaty B, Goff DC Jr (2009) Angiotensin-converting enzyme inhibitors and cognitive decline in older adults with hypertension: Results from the cardiovascular health study. Arch Intern Med 169, 1195-1202
39. Solfrizzi V, Scafato E, Frisardi V, Seripa D, Logroscino G, Kehoe PG, Imbimbo BP, Baldereschi M, Crepaldi G, Di Carlo A, Galluzzo L, Gandin C, Inzitari D, Maggi S, Pilotto A, Panza F, Group ftILSoAW (2011) Angiotensin-converting enzyme inhibitors and incidence of mild cognitive impairment. The Italian Longitudinal Study on Aging. Age, doi: 10.1007/s11357-011-9360-zz
40. Ohrui T, Tomita N, Sato-Nakagawa T, Matsui T, Maruyama M, Niwa K, Arai H, Sasaki H (2004) Effects of brainpenetratingACEinhibitors on Alzheimer disease progression. Neurology 63, 1324-1325
41. Deschaintre Y, Richard F, Leys D, Pasquier F (2009) Treatment of vascular risk factors is associated with slower decline in Alzheimer disease. Neurology 73, 674-680
42. McGuinness B, Todd S, Passmore P, Bullock R (2009) Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. Cochrane Database Syst Rev (4), CD004034
43. Kehoe PG, PassmoreAP(2012) The renin-Angiotensin system and antihypertensive drugs in Alzheimer's disease: Current standing of the angiotensin hypothesis? J Alzheimers Dis 30(SUPPL2), S251-S268
44. Richard E, Kuiper R, Dijkgraaf MG, Van Gool WA (2009) Vascular care in patients with Alzheimer's disease with cerebrovascular lesions-A randomized clinical trial. J Am Geriatr Soc 57, 797-805
45. Hoffman LB, Schmeidler J, Lesser GT, Beeri MS, Purohit DP, Grossman HT, Haroutunian V (2009) Less Alzheimer disease neuropathology in medicated hypertensive than nonhypertensive persons. Neurology 72, 1720-1726